Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics Inc (NQ: IOVA )

8.550 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
(IOVA) - Analyzing Iovance Biotherapeutics's Short Interest
Via Benzinga
Why Iovance Biotherapeutics Stock Got Trounced on Thursday
A robust rally ended abruptly with the publication of the company's latest fundamentals. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Spotlight on Iovance Biotherapeutics: Analyzing the Surge in Options Activity
Via Benzinga
Iovance Therapeutics Stock Has Skyrocketed Over 100% so Far This Year. Is It Still a Buy?
More gains might be on the way for this high-flying biotech stock. 
Via The Motley Fool
Iovance Biotherapeutics: Q4 Earnings Insights
Via Benzinga
Iovance Biotherapeutics's Earnings: A Preview
Via Benzinga
Is Iovance a Buy After Its First Regulatory Win?
Iovance Biotherapeutics has found a new way to treat cancer. 
Via The Motley Fool
Unpacking the Latest Options Trading Trends in Iovance Biotherapeutics
Via Benzinga
Iovance Biotherapeutics Unusual Options Activity For February 22
Via Benzinga
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
3 Stocks Flashing Recent Insider Buying Signals
One way to spot an opportunity is by paying attention to insider buying stocks. After all, it’s the insiders that know their company. 
Via InvestorPlace
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential. 
Via InvestorPlace
1 Soaring Growth Stock That Could Rise Another 53%, According to Wall Street
A successful launch of its first approved therapy could push shares of this innovative new cancer drug developer through the roof. 
Via The Motley Fool
This Biotech Stock Has 47% Upside, According to 1 Wall Street Analyst
It has good news in hand and plenty of room to grow. 
Via The Motley Fool
Why Iovance Biotherapeutics Stock Is Skyrocketing Today
Iovance is no longer a clinical-stage biotech. 
Via The Motley Fool
2 Top Biotech Stocks That Wall Street Thinks Could Soon Double in Value
These two businesses have viable paths to making investors richer -- possibly soon. 
Via The Motley Fool
Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of International Flavors & Fragrances Inc. (NYSE: IFF) fell during Wednesday’s session after the company reported mixed fourth-quarter financial results and reduced its expected quarterly... 
Via Benzinga
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) Near Top of Volume Charts in Wednesday Trading
Via Investor Brand Network
Toll Brothers Posts Upbeat Earnings, Joins Exelon, Garmin, Bausch + Lomb And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Nasdaq Composite falling more than 100 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results. 
Via Benzinga
Why Is Iovance Therapeutics (IOVA) Stock Up 35% Today?
With Iovance Therapeutics gaining FDA approval for its novel skin cancer therapeutic, IOVA stock is proving the bears wrong. 
Via InvestorPlace
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) Near Top of Volume Charts in Tuesday Trading
Via Investor Brand Network
Walmart Posts Upbeat Earnings, Joins Armstrong World Industries, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mostly lower, with the Nasdaq Composite falling more than 200 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Iovance Biotherapeutics Stock?
Iovance Biotherapeutics announced Tuesday that the U.S. Food and Drug Administration (FDA) approved the company to begin analytical testing and manufacturing of AMTAGVI at its Philadelphia site.... 
Via Benzinga
Alaska Air To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.